Hero image with Pittsburgh background https://pittplusme.org/study/1839

We're sorry. This study is closed and no longer recruiting participants.

STUDY BASICS

Have you been diagnosed with an ulcerative form of pyoderma gangrenosum? You may be able to participate in a study to see if an investigational study drug called IFX-1 is safe and effective to treat pyoderma gangrenosum. This study involves 19 visits over 9 months. Compensation is provided.


IRB: 20192885
- OPEN LABEL EXPLORATORY PHASE IIA TRIAL TO INVESTIGATE THE SAFETY AND EFFICACY OF IFX-1 IN TREATING SUBJECTS WITH PYODERMA GANGRENOSUM (OPTIMA)

Age Range
AGE:   18 and up
Duration
DURATION:  9 months
VISITS:  19
Location
LOCATION:  Falk Medical Building - Oakland
Compensation
COMPENSATION:  $175 for baseline visit & $75 per visit for all other visits
Location
PHONE NUMBER: 1-866-438-8230
SHARE STUDY
Printer Printer   Email A FriendEmail A Friend   ShareShare   TweetTweet   Linked-InLinked-In

INTERESTED?

Visit https://pittplusme.org/study/1839 and click on "I'm Interested" or call 1-866-438-8230.

LEARN MORE

PittPlusMe.org
1-866-438-8230
PittPlusMe@pitt.edu
@PittPlusMe
@PittPlusMe

MEET THE RESEARCHER


Laura Ferris

Laura Korb Ferris, MD, PhD, is Professor of Dermatology at the University of Pittsburgh School of Medicine, and is also the Director of Clinical Trials for the Department of Dermatology. Dr. Ferris earned her doctorate in immunology from Johns Hopkins University and her medical degree from the University of Maryland.